Oliver Lagore Vanvalin Investment Group’s Novo Nordisk NVO Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$977K	Buy	+14,067	New	+$957K	0.38%	63
2024 Q4	$2.1M	Buy	24,420 +8,693	+55%	+$940K	0.54%	38
2024 Q3	$1.87M	Sell	15,727 -694	-4%	-$92.6K	0.5%	41
2024 Q2	$2.34M	Buy	16,421 +1,591	+11%	+$211K	0.67%	27
2024 Q1	$1.9M	Buy	14,830 +2,739	+23%	+$326K	0.56%	33
2023 Q4	$1.25M	Buy	12,091 +4,945	+69%	+$489K	0.47%	36
2023 Q3	$650K	Buy	7,146 +2,856	+67%	+$252K	0.26%	61
2023 Q2	$347K	Buy	4,290 +2,488	+138%	+$203K	0.13%	108
2023 Q1	$143K	Buy	1,802 +1,776	+6,831%	+$126K	0.06%	105
2022 Q4	$1.76K	Hold	26	–	–	﹤0.01%	565
2022 Q3	$1K	Buy	+26	New	+$1.39K	﹤0.01%	594

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's NVO Position: Q2 2025 in Review

Oliver Lagore Vanvalin Investment Group opened a new position in Novo Nordisk (NVO) in Q2 2025: 14,067 shares worth $977K. The stake represents 0.38% of the portfolio and ranks #63 among its holdings. This is a return to the name: Oliver Lagore Vanvalin Investment Group previously reported a position in NVO as recently as Q4 2024.

Oliver Lagore Vanvalin Investment Group first reported a position in NVO in Q3 2022 and has held it in 11 quarters since. The position peaked at $2.34M in Q2 2024. 1,482 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

Oliver Lagore Vanvalin Investment Group held 14,067 shares of Novo Nordisk worth $977K as of Q2 2025.
Novo Nordisk was a new Oliver Lagore Vanvalin Investment Group position in Q2 2025.
Novo Nordisk made up 0.38% of Oliver Lagore Vanvalin Investment Group's portfolio in Q2 2025, its #63 holding.
Oliver Lagore Vanvalin Investment Group first reported a position in Novo Nordisk in Q3 2022 and has held it in 11 quarters since.
Oliver Lagore Vanvalin Investment Group's Novo Nordisk position peaked at $2.34M in Q2 2024.
1,482 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2025, filed 10 Jul 2025.